Fox Run Management L.L.C. purchased a new stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 69,185 shares of the biopharmaceutical company's stock, valued at approximately $883,000. Fox Run Management L.L.C. owned about 0.05% of Dynavax Technologies as of its most recent SEC filing.
A number of other large investors have also recently made changes to their positions in the stock. Smartleaf Asset Management LLC boosted its holdings in Dynavax Technologies by 463.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 2,034 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Dynavax Technologies by 55.1% in the 4th quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company's stock worth $52,000 after buying an additional 1,457 shares during the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new stake in shares of Dynavax Technologies in the fourth quarter worth $71,000. Nisa Investment Advisors LLC increased its position in Dynavax Technologies by 19.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company's stock valued at $83,000 after acquiring an additional 1,076 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB bought a new position in Dynavax Technologies in the third quarter valued at about $89,000. 96.96% of the stock is currently owned by institutional investors.
Dynavax Technologies Stock Performance
NASDAQ DVAX traded up $0.14 on Thursday, reaching $13.72. 1,213,631 shares of the stock were exchanged, compared to its average volume of 1,998,251. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. Dynavax Technologies Co. has a one year low of $9.74 and a one year high of $14.63. The firm has a market capitalization of $1.70 billion, a PE ratio of 76.22 and a beta of 1.23. The company's 50-day simple moving average is $13.29 and its two-hundred day simple moving average is $12.46.
Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last released its earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, meeting analysts' consensus estimates of $0.05. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. The company had revenue of $72.03 million for the quarter, compared to analysts' expectations of $72.70 million. Analysts expect that Dynavax Technologies Co. will post 0.32 EPS for the current fiscal year.
Analysts Set New Price Targets
DVAX has been the subject of a number of recent research reports. William Blair restated an "outperform" rating on shares of Dynavax Technologies in a research note on Friday, February 21st. StockNews.com raised shares of Dynavax Technologies from a "hold" rating to a "buy" rating in a report on Monday, February 24th. HC Wainwright reiterated a "buy" rating and set a $31.00 price target on shares of Dynavax Technologies in a research note on Friday, February 21st. Finally, The Goldman Sachs Group lowered Dynavax Technologies from a "neutral" rating to a "sell" rating and reduced their price objective for the stock from $15.00 to $12.00 in a research note on Tuesday, February 11th.
View Our Latest Report on Dynavax Technologies
About Dynavax Technologies
(
Free Report)
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
Further Reading
Before you consider Dynavax Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dynavax Technologies wasn't on the list.
While Dynavax Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
